Clinical trials: Non-small Cell Lung Carcinoma
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery…
- Conditions
- Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
- Trial name
- LOTUS (NCT06073431)
- Testing
- Biospecimen Collection, Computed Tomography, Electronic Health Record Review
- Where
- 225 sites in United States
- Volunteers
- 800 people
- Sponsor
- University of Rochester
Non Squamous Non Small Cell Lung Cancer
A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer
The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P51 and European Union (EU) approved Keytruda in combination with platinum pemetrexed chemotherapy in patients with previously untreated metastatic…
- Trial name
- NCT06939595
- Testing
- CT-P51, EU-approved Keytruda
- Where
- Georgia
- Volunteers
- 225 people
- Sponsor
- Celltrion
Non Small Cell Lung Cancer, Small Cell Lung Cancer
Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies
Hypothesis 1- Using IMRT, the radiation therapy (RT) dose can be safely escalated from 58 Gy to 74 Gy given as 6 fractions/week with concurrent chemotherapy.
- Conditions
- Non Small Cell Lung Cancer, Small Cell Lung Cancer, Thymoma, Thymus Neoplasms
- Trial name
- ESIMRT (NCT00921739)
- Testing
- Esophageal sparing IMRT
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Lung Non-Small Cell Carcinoma, Stage I Colorectal Cancer AJCC v8
Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer
This phase III trial studies how well a telehealth self-management program works in improving survivorship care and outcomes in stage I-III non-small cell lung cancer or colorectal cancer survivors.
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Colorectal Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8
- Trial name
- NCT04428905
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Survivorship Care Plan
- Where
- United States
- Volunteers
- 403 people
- Sponsor
- City of Hope Medical Center
Non-small Cell Lung Cancer (NSCLC)
A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer
The objective of the proposed clinical trial is to investigate the safety and tolerability of CV301 in combination with Anti-PD1-Therapy in subjects with non-small cell lung cancer (NSCLC).
- Trial name
- NCT02840994
- Testing
- CV301, Pembrolizumab, Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Bavarian Nordic
Non Small Cell Lung Cancer
Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer
Lung cancer is one of the diseases with the highest global incidence and mortality. Studies have confirmed that liquid biopsy markers such as minimal residual disease (MRD) detection in solid tumors, circulating tumor DNA…
- Trial name
- NCT07057102
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-Small Cell Lung Cancer
Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy
This clinical study investigates whether adding local radiation therapy (radiotherapy) to standard maintenance therapy benefits patients with advanced non-small cell lung cancer (NSCLC) who have a limited number of residual…
- Trial name
- NCT07014202
- Testing
- Immunotherapy (with or without chemotherapy) maintenance therapy combined with radiotherapy, Immunotherapy (with or without chemotherapy) maintenance therapy
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer, Lung Cancer
HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer
RATIONALE: Vaccines made from the HER2/neu antigen may make the body build an immune response and kill tumor cells. Colony-stimulating factors such as GM-CSF increase the number of immune cells found in bone marrow or peripheral…
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00003002
- Testing
- HER-2/neu peptide vaccine, sargramostim
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Washington
Malignant Pleural Mesothelioma, Non-small Cell Lung Cancer
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
A significant number of patients with malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC) are not cured with available treatments and will eventually relapse. After relapse treatment options are limited.
- Trial name
- NCT04480372
- Testing
- Gemcitabine, Atezolizumab
- Where
- 12 sites in Switzerland
- Volunteers
- 68 people
- Sponsor
- Swiss Cancer Institute
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer
This phase I trial studies the side effects of soy isoflavones when given together with radiation therapy and chemotherapy in treating patients with stage IIIA-IIIB non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer
- Trial name
- NCT01958372
- Testing
- soy isoflavones, cisplatin, etoposide
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Squamous Non Small Cell Lung Cancer
A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of HLX10 + chemotherapy vs chemotherapy in subjects with locally advanced or metastatic squamous NSCLC…
- Trial name
- NCT04033354
- Testing
- HLX10, carboplatin and nab paclitaxel
- Where
- 92 sites in United States, China and 5 more
- Volunteers
- 537 people
- Sponsor
- Shanghai Henlius Biotech
MTAP-deleted Solid Tumors
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have…
- Trial name
- NCT06188702
- Testing
- S095035, TNG462
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 61 people
- Sponsor
- Servier Bio-Innovation LLC
Non-Squamous Non-Small Cell Lung Cancer
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with Tarceva (erlotinib) in participants with incurable non-small cell lung cancer…
- Trial name
- NCT01456325
- Testing
- Erlotinib, Onartuzumab (MetMab)
- Where
- 213 sites in United States, Argentina and 25 more
- Volunteers
- 494 people
- Sponsor
- Genentech, Inc.
Advanced Non-small Cell Lung Cancer
Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer
This is an open-label, multi-center, Phase 2 study in subjects with treatment-naïve locally advanced (unresectable and unable to receive radical chemoradiotherapy) or metastatic PD-L1-positive non-small cell lung cancer (NSCLC)…
- Trial name
- NCT05420220
- Testing
- KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection), Axitinib
- Where
- 6 sites in China
- Volunteers
- 95 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NSCLC Stage IV
Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer
Patients were randomized to microwave ablation plus camrelizumab group or camrelizumab group.
- Trial name
- MWA in NSCLC (NCT04102982)
- Testing
- Camrelizumab, Camrelizumab plus microwave ablation
- Where
- 13 sites in China
- Volunteers
- 200 people
- Sponsor
- Shandong Provincial Hospital
Lung Cancer
Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00287989
- Testing
- Carboplatin, erlotinib hydrochloride, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 86 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent Non-small Cell Lung Cancer
A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer
Drugs used in chemotherapy, such as 3-AP and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving 3-AP together with gemcitabine may kill more tumor cells.
- Trial name
- NCT00077350
- Testing
- triapine, gemcitabine hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed or Refractory Solid Tumors, Nonsmall Cell Lung Cancer
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer
For the phase I component of the trial a classic 3 + 3 dose escalation design will be utilized, with a fixed dose of pembrolizumab and an escalating dose of the lenalidomide.
- Trial name
- NCT02963610
- Testing
- Lenalidomide, Pembrolizumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fox Chase Cancer Center
Brain Metastases
Prophylactic Cranial Irradiation (PCI) Versus no PCI in Non Small Cell Lung Cancer After a Response to Chemotherapy
1. Patients with confirmed advanced NSCLC and any response to 3-6 cycles of chemotherapy, were randomized to receive PCI (30 Gy/10fr) or no PCI. 2.
- Trial name
- PCI (NCT00745797)
- Testing
- Radiotherapy
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Yi-Long Wu
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent With Metastatic Lung Cancer
The purpose of this study is to investigate the safety and imaging ability of 111In-DAC when used with planar and SPECT imaging for the detection of lung cancer and brain cancer consistent with metastatic lung cancer.
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Metastases, Neoplasm
- Trial name
- NCT00040560
- Testing
- 111In-DAC, Diagnostic
- Where
- 2 sites in United States
- Sponsor
- Copharos
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.